Vaxxirna is a biotechnology company developing next-generation infectious disease vaccines powered by its proprietary viRNA™ circular RNA platform.

The company is focused on advancing vaccines designed to overcome key limitations of first-generation linear mRNA technologies, including short-lived immune responses, cold-chain dependence, tolerability challenges, and traditional needle-based administration. Through its innovative circular RNA platform, Vaxxirna is developing vaccine solutions engineered for durable immune protection, thermostability, and patient-friendly delivery.

By combining advanced RNA engineering, thermostable lipid nanoparticle formulations, and microneedle patch technology, Vaxxirna is building a platform designed to improve vaccine accessibility, simplify global distribution, and support real-world deployment across diverse healthcare settings.

Vaxxirna is advancing a focused pipeline of infectious disease vaccine programs while leveraging a scalable platform approach to accelerate development, generate cross-program insights, and address current and emerging global health threats.

The company welcomes engagement from investors, strategic partners, scientific collaborators, and organizations committed to advancing the future of infectious disease prevention.

General Inquiries: info@vaxxirna.com

Website: www.vaxxirna.com

Vaxxirna

Org chart

Teams

Offices

Vaxxirna

Org chart

Teams

Offices

Related companies